Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-12/IL-23 p40/IL12B drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-12/IL-23 p40 (IL12B) Recombinant Protein / Mutant Panel High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 Expressed for native glycosylation and proper disulfide-mediated dimerization competence. |
View IL12B Products |
| Gene Delivery | IL12B Promise-ORF / Lentivirus Full-length ORF for stable cell line generation; secreted expression for functional cytokine release assays. |
View IL12B Products |
| Benchmark Ab | Anti-IL-12/IL-23 p40 (Ustekinumab Sequence) Recombinant positive control for assay standardization; sequence-verified IgG1, endotoxin controlled. |
View IL12B Products |
| Validator | IL12B siRNA Set For specific knockdown verification of p40 expression in cell-based models. |
View IL12B Products |
| Related Target A | IL23A (p19) Synergistic subunit forming the IL-23 heterodimer; crucial for specific Th17 pathway targeting and selectivity assays. |
View IL23A Products |
| Related Target B | IL12A (p35) Partner subunit for IL-12 heterodimer formation; essential for assessing p40-mediated IL-12 signaling blockade. |
View IL12A Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Heterodimer complex formation (p40+p19 / p40+p35) | High-purity human p40 protein expressed in HEK293 with verified disulfide bond integrity; available as monomeric, homodimeric, and complex-ready formats. |
| Cross-species evaluation (human/cyno/mouse) | Human / Cynomolgus / Mouse IL12B ortholog proteins available with >95% purity and sequence verified by mass spectrometry. |
| Heterodimer vs free p40 epitope discrimination | Ustekinumab benchmark antibody and p40 mutant panel enable precise epitope mapping and binning assays. |
| Lack of reliable controls | Clinical benchmark antibodies (biosimilars) included with sequence-verified integrity. |
| False positives in functional assays | Validated IL12B siRNA and species-specific protein panel included for rigorous specificity controls. |
Protein Domains and Key Mutations
IL12B (p40) contains two key functional domains:
- Ig-like C2-type domain (UniProt P29460)
- Fibronectin type-III domain (UniProt P29460)
Clinically relevant mutations:
- dbSNP:rs3213096 (UniProt VAR_020001)
- dbSNP:rs3213119 (UniProt VAR_049170)
These variants may influence protein expression, dimerization, or drug response and are critical for patient stratification and biosimilar development.
Live IL-12/IL-23 p40/IL12B R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-12/IL-23 p40/IL12B therapeutics has fundamentally shaped the treatment of psoriasis, Crohn's disease, and ulcerative colitis. As first-generation blockbuster therapies reach patent cliffs, the next wave of R&D is intensely focused on biosimilar development, improved subcutaneous formulations, and next-generation bispecific antibodies. Developers are balancing the broad immunosuppression of p40 targeting against the hyper-specific inhibition of the IL-23 p19 subunit, requiring highly precise assay reagents to validate mechanism of action and safety profiles.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (mAbs) | Johnson & Johnson, Amgen, Alvotech | Psoriasis, Crohn's Disease, Ulcerative Colitis | Kinetics Validation (Need high-purity, native-folded heterodimers) |
| Bispecific Antibodies | Janssen, Eli Lilly | Refractory Autoimmune Disorders | Heterodimer Specificity (Need cross-reactive and subunit-specific Abs) |
| Biosimilars | Formycon, Bio-Thera Solutions | Plaque Psoriasis, Inflammatory Bowel Disease | Bioequivalence Testing (Need Benchmark Abs and high-spec antigens) |